Drugs Made In America Acquisition II (NASDAQ:DMII) Trading at $10.20

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII)’s share price shot up 0% during mid-day trading on Friday. The company traded as high as $10.19 and last traded at $10.1950. 600,242 shares changed hands during mid-day trading, an increase of 458% from the average session volume of 107,597 shares. The stock had previously closed at $10.19.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a report on Tuesday, September 1st. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Drugs Made In America Acquisition II currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Price Performance

The company’s fifty day moving average is $10.15 and its 200 day moving average is $10.09.

Drugs Made In America Acquisition II (NASDAQ:DMII) last posted its earnings results on Friday, August 14th. The company reported $0.07 earnings per share for the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of DMII. Magnetar Financial LLC purchased a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter valued at about $26,730,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Drugs Made In America Acquisition II in the 1st quarter worth approximately $19,960,000. Aristeia Capital L.L.C. purchased a new position in Drugs Made In America Acquisition II in the 4th quarter worth approximately $10,890,000. OMERS ADMINISTRATION Corp acquired a new stake in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $9,900,000. Finally, Context Capital Management LLC acquired a new stake in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $7,425,000.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II Corp. is a special purpose acquisition company (SPAC) organized to identify and complete a business combination with one or more businesses. The company does not operate a commercial business of its own and was formed to raise capital through a public offering for the purpose of pursuing a merger, acquisition or similar transaction.

Based on its name and public company filings, Drugs Made In America Acquisition II is focused on opportunities involving the pharmaceutical and healthcare sectors, with an emphasis on businesses connected to drug manufacturing in the United States.